Antiplatelet deescalation after DES may not benefit patients at high ischemic risk

MUNICH — In patients at high ischemic risk implanted with a drug-eluting stent who had 12 months of dual antiplatelet therapy, switching to clopidogrel monotherapy increased ischemic events but reduced bleeding events, a speaker reported. Byeong-Keuk Kim, MD, PhD, professor in the department of internal medicine at Yonsei University College of Medicine in Seoul, South Korea, said